Get the Stockscreener App
1.20
0.41%
-0.005
After Hours:
1.21
0.01
+0.83%
Opus Genetics Inc stock is traded at $1.20, with a volume of 208.70K.
It is down -0.41% in the last 24 hours and up +1.69% over the past month.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
See More
Previous Close:
$1.205
Open:
$1.22
24h Volume:
208.70K
Relative Volume:
0.21
Market Cap:
$71.89M
Revenue:
$8.38M
Net Income/Loss:
$-27.19M
P/E Ratio:
-1.1009
EPS:
-1.09
Net Cash Flow:
$-13.59M
1W Performance:
+3.45%
1M Performance:
+1.69%
6M Performance:
+15.38%
1Y Performance:
+0.00%
1-Day Range:
$1.18
$1.25
1-Week Range:
$1.12
$1.27
52-Week Range:
$0.65
$1.75
Opus Genetics Inc Stock (IRD) Company Profile
Name
Opus Genetics Inc
Sector
Industry
Phone
248-681-9815
Address
8 DAVIS DRIVE, DURHAM
Compare IRD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
1.20 | 72.19M | 8.38M | -27.19M | -13.59M | -1.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-11-25 | Initiated | Craig Hallum | Buy |
| Nov-13-24 | Resumed | H.C. Wainwright | Buy |
Opus Genetics Inc Stock (IRD) Latest News
Is Opus Genetics Inc. trending in predictive chart models2025 Market Sentiment & Weekly High Return Opportunities - Newser
Opus Genetics Inc. stock outlook for YEAR2025 Technical Overview & Low Drawdown Trading Strategies - Newser
Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September - GlobeNewswire
One-Year Clinical Data: Opus Genetics' Revolutionary Gene Therapy for Inherited Retinal Disease at Global Forums - Stock Titan
What does recent volatility data suggest for Opus Genetics Inc.2025 Historical Comparison & Stepwise Trade Signal Implementation - Newser
Developing predictive dashboards with Opus Genetics Inc. data2025 Sector Review & Growth Focused Stock Pick Reports - Newser
Visualizing Opus Genetics Inc. stock with heatmapsAnalyst Upgrade & Verified Swing Trading Watchlists - Newser
Can Opus Genetics Inc. rally from current levelsCEO Change & Entry Point Confirmation Signals - Newser
Opus Genetics completes $3.5 million private placement of common stock By Investing.com - Investing.com Australia
Opus Genetics: A Strategic Capital Raise Fuels Gene Therapy Ambitions in Inherited Retinal Diseases - AInvest
Opus Genetics Inc enters agreements for private placement of shares - MarketScreener
Is Opus Genetics Inc. still a buy after recent gainsCPI Data & Weekly High Return Forecasts - theviewers.co.kr
Market Overview: Is Opus Genetics Inc. benefiting from innovation trendsTrade Analysis Report & Target Return Focused Picks - theviewers.co.kr
Will Opus Genetics Inc. outperform the marketJuly 2025 Movers & Technical Pattern Based Buy Signals - Newser
Using flow based indicators on Opus Genetics Inc.Weekly Market Report & Daily Chart Pattern Signals - Newser
Can Opus Genetics Inc. expand its profit marginsJuly 2025 WrapUp & AI Enhanced Trade Execution Alerts - sundaytimes.kr
Are Bears Losing Grip on Opus Genetics Inc.July 2025 Movers & Free Reliable Trade Execution Plans - kangso.co.kr
Can Opus Genetics Inc. Regain Lost Ground This QuarterInsider Selling & Free Safe Entry Trade Signal Reports - newsyoung.net
Opus Genetics Inc. stock chart pattern explainedProduct Launch & Fast Entry Momentum Alerts - Newser
Quant Funds Rotate Into Opus Genetics Inc. StockTrade Risk Assessment & Safe Entry Momentum Stock Tips - 더경남뉴스
Why Opus Genetics Inc. stock attracts strong analyst attentionWeekly Loss Report & Verified Momentum Stock Ideas - Newser
How Opus Genetics Inc. stock reacts to Fed policy changes2025 Trade Ideas & Weekly Momentum Picks - Newser
Quantitative breakdown of Opus Genetics Inc. recent moveTrend Reversal & Precise Buy Zone Identification - Newser
How to integrate Opus Genetics Inc. into portfolio analysis toolsJuly 2025 Market Mood & High Return Trade Guides - Newser
Night Vision Disturbances Market to Experience Notable Growth - openPR.com
Night Vision Disturbances Market to Experience Notable Growth by 2034, DelveInsight Predicts | Ocuphire Pharma, Viatris - The Globe and Mail
Opus Genetics’ OPGx-BEST1 cleared to enter clinic - BioWorld MedTech
FDA clears Opus Genetics' IND for BEST1 IRD gene therapy - Eyes On Eyecare
Opus Genetics announces FDA clearance of IND application for gene therapy candidate OPGx-BEST1 - Eyes On Eyecare
Promising Developments and Financial Stability Drive Buy Rating for Opus Genetics - TipRanks
Opus Genetics shares fall 4.17% intraday after FDA clearance of IND for OPGx-BEST1 gene therapy. - AInvest
Opus Genetics announces FDA clearance of IND application for OPGx-BEST1 - TipRanks
Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1 - GlobeNewswire
First Gene Therapy IND for Best Disease: Opus Genetics' BEST1 Treatment Advances to Clinical Trials - Stock Titan
What high frequency data says about Opus Genetics Inc.Quarterly Earnings Summary & Reliable Price Breakout Signals - Newser
Opus Genetics reports Q2 EPS (12c) vs (30c) last year - MSN
Earnings visualization tools for Opus Genetics Inc.Earnings Performance Report & Real-Time Chart Breakout Alerts - Newser
Is Opus Genetics Inc. stock reversal real or fakePortfolio Update Summary & AI Forecasted Stock Moves - Newser
Sentiment analysis tools applied to Opus Genetics Inc.Short Setup & Free Technical Pattern Based Buy Signals - Newser
Automated trading signals detected on Opus Genetics Inc.Quarterly Trade Summary & Real-Time Sentiment Analysis - Newser
What to do if you’re stuck in Opus Genetics Inc.2025 Market Outlook & Capital Efficient Trade Techniques - Newser
How to monitor Opus Genetics Inc. with trend dashboardsWeekly Risk Report & Risk Controlled Daily Plans - Newser
Can a trend reversal in Opus Genetics Inc. lead to recovery2025 Top Gainers & High Conviction Buy Zone Alerts - Newser
Opus Genetics, Inc. (NASDAQ:IRD) Just Reported Earnings, And Analysts Cut Their Target Price - ca.finance.yahoo.com
How liquid is Opus Genetics Inc. stockPortfolio Return Summary & High Yield Stock Recommendations - thegnnews.com
Volatility clustering patterns for Opus Genetics Inc.2025 Market Outlook & Fast Momentum Stock Entry Tips - Newser
Foundation Fighting Blindness, Inc. Net Worth (2025) - GuruFocus
Price momentum metrics for Opus Genetics Inc. explainedAnalyst Upgrade & Breakout Confirmation Alerts - Newser
Trendlines Converge — Decision Point for Opus Genetics Inc.2025 AllTime Highs & Daily Stock Momentum Reports - beatles.ru
Opus Genetics: Promising Clinical Trials and Strategic Partnerships Drive Buy Rating - TipRanks
Opus Genetics Inc Stock (IRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):